Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Herpes Zoster vaccine · 3 trials · 2 indications
Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]; For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
The number of days with any local symptoms during the solicited post-vaccination period.
Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
The number of days with general symptoms during the solicited post-vaccination period.
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (≥) 4 fold the cut-off for Anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]. For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre-vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination
| Arm | Type | Description |
|---|---|---|
| HZ/su Lot A | EXPERIMENTAL | Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot. |
| HZ/su Lot B | EXPERIMENTAL | Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot. |
| HZ/su Lot C | EXPERIMENTAL | Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot. |
| HZ Group | EXPERIMENTAL | Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2. |
| Vaccine Group | EXPERIMENTAL | Subjects will receive the candidate HZ vaccine (GSK 1437173A). |
| Placebo Group | PLACEBO_COMPARATOR | Subjects will receive the placebo vaccine. |
| Name | Type | Description |
|---|---|---|
| Herpes Zoster vaccine (GSK 1437173A) | BIOLOGICAL | 2 doses administered intramuscularly in deltoid region of non-dominant arm. |
| Herpes Zoster vaccine (GSK1437173A) | BIOLOGICAL | 2 doses administered intramuscularly in deltoid region of non-dominant arm. |
| Placebo | DRUG | 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1. |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * A male or female aged 50 years or older at the time of the first vaccination. * Written informed consent obtained from the subject. * Female subjects of non-childbear...
Herpes Zoster vaccine is used for the prevention of herpes zoster, commonly known as shingles. It is being developed by GSK plc for adults, including those aged 18 years and older with blood cancers and adults aged 50 years and older with a prior episode of herpes zoster.
Herpes Zoster vaccine is being developed by GSK plc, a biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 3 clinical development for the prevention of herpes zoster.
Herpes Zoster vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Three Phase 3 trials have been completed, with a total enrollment of 1,315 participants.
Herpes Zoster vaccine has completed three Phase 3 trials: NCT01767467 in adults with blood cancers, NCT01827839 in adults with a prior episode of herpes zoster, and NCT02075515 in adults aged 50 years and older. All trials are completed and enrolled a total of 1,315 participants.
Herpes Zoster vaccine is also known as the Herpes Zoster Subunit (HZ/su) vaccine and GSK1437173A. These names refer to the same investigational vaccine being developed by GSK plc for the prevention of herpes zoster.